Transgenomic (NASDAQ:PRPO) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.
Shares of Transgenomic (PRPO) opened at $1.29 on Friday. Transgenomic has a fifty-two week low of $1.18 and a fifty-two week high of $47.70. The company has a quick ratio of 0.07, a current ratio of 0.08 and a debt-to-equity ratio of 0.01.
WARNING: This report was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.com-unik.info/2017/12/03/valuengine-upgrades-transgenomic-prpo-to-sell.html.
Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.
What are top analysts saying about Transgenomic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Transgenomic Inc. and related companies.